Table 3—

Additional characteristics of subjects included in the five clusters defined by the agnes method

Cluster
12345
Subjects n1514307838
Male11 (73.3)12 (85.7)19 (63.3)46 (59.0)21 (55.3)
Macroscopic emphysema#5 (33.3)3 (21.4)1 (3.3)1 (1.3)1 (2.6)
PEF variability6 (40.0)4 (28.6)4 (13.3)7 (9.0)8 (21.1)
Eczema7 (46.7)5 (35.7)15 (50.0)29 (37.2)19 (50.0)
Rhinitis11 (73.3)3 (21.4)26 (86.7)46 (59.0)27 (71.1)
Hospitalised+ ever4 (26.7)2 (14.3)8 (26.7)10 (12.8)9 (23.7)
Hospitalised+ in last year1 (6.7)0 (0)0 (0)1 (1.3)4 (10.5)
Inhaled β2-agonist8 (53.3)4 (28.6)13 (43.3)22 (28.2)13 (34.2)
Inhaled corticosteroids4 (26.7)3 (21.4)10 (30.3)18 (23.1)16 (42.1)
Inhaled antimuscarinic0 (0)1 (17.1)0 (0)0 (0)1 (2.6)
Any inhaler8 (53.3)5 (35.7)14 (46.7)29 (32.1)17 (44.7)
Age yrs64.7±7.665.5±8.652.4±14.656.1±14.558.2±11.6
Eosinophils 109 cells·L−10.27±0.170.21±0.190.22±0.090.18±0.140.27±0.16
MMEF % pred28.6±12.934.1±13.958.9±25.169.6±22.966.9±24.5
sGaw % pred46.6±28.952.3±24.061.6±22.977.0±26.273.3±29.2
Maximum PEF variability§22.5±15.016.8±14.412.2±8.410.9±7.013.9±16.4
SGRQ score28.0±18.221.9±16.812.6±11.99.9±11.123.6±18.3
  • Data are presented as mean±sd or n (%), unless otherwise indicated. PEF: peak expiratory flow; MMEF: maximal mid-expiratory flow; % pred: % predicted; sGaw: specific airway conductance; SGRQ: St George’s Respiratory Questionnaire. #: radiological (computed tomography) evidence of definite emphysematous changes; : variability of >20% during 1 week of testing; +: due to respiratory disorder; §: amplitude of mean.